Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jing-Ya Zhong"'
Autor:
Kang Wang, Zong-Han Liu, Hong-Ming Yu, Yu-Qiang Cheng, Yan-Jun Xiang, Jing-Ya Zhong, Qian-Zhi Ni, Li-Ping Zhou, Chao Liang, Hong-Kun Zhou, Wei-Wei Pan, Wei-Xing Guo, Jie Shi, Shu-Qun Cheng
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Anti-programmed cell death ligand 1/vascular endothelial growth factor inhibition, coupled with chemotherapy, may potentiate antitumor immunity leading to enhanced clinical benefit, but it has not been investigated in advanced biliary tra
Externí odkaz:
https://doaj.org/article/7ddc1949430f42c7b30f2a22cd31a782
Autor:
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Jing-Ya Zhong, Shuang Feng, Qian-Zhi Ni, Hong-Fei Zhu, Wei-Wei Pan, Jing-Jing Li, Chao Liang, Hong-Kun Zhou, Yan Meng, Wan Yee Lau, Shu-Qun Cheng
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Background and aimsThe efficacy and safety of systemic atezolizumab and bevacizumab (atezo/bev) in treatment of patients with unresectable hepatocellular carcinoma (HCC) have been demonstrated. However, the efficacy of this treatment in patients with
Externí odkaz:
https://doaj.org/article/d03d269f9724481fb5da843f4f3ccb18
Autor:
Kang Wang, Zong-Han Liu, Hong-Ming Yu, Yu-Qiang Cheng, Yan-Jun Xiang, Jing-Ya Zhong, Qian-Zhi Ni, Li-Ping Zhou, Chao Liang, Hong-Kun Zhou, Wei-Wei Pan, Wei-Xing Guo, Jie Shi, Wan Yee Lau, Shu-Qun Cheng
Background: Anti-PD-L1/VEGF inhibition, coupled with chemotherapy, may potentiate antitumor immunity leading to enhanced clinical benefit, but it has not been investigated in advanced biliary tract cancer (BTC). We investigated the efficacy and safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52a53122ce9293075424040adcfb4d6e
https://doi.org/10.21203/rs.3.rs-2149321/v1
https://doi.org/10.21203/rs.3.rs-2149321/v1
